Clindamycin as Antimicrobial Treatment for Streptococcus Spp. PeRiprosthetic Infection

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07335627

Acronym

CASPR

Enrollment

260

Registered

2026-01-13

Start date

2025-02-21

Completion date

2026-07-21

Last updated

2026-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Streptococcus Infection

Keywords

Streptococcus Infection, Clindamycin, Antimicrobial Treatment, Osteoarticular infections, Amoxicillin

Brief summary

Clindamycin is an antibiotic with several advantages: high oral bioavailability and good bone and joint penetration. In France, it is a recommended drug for other types of Streptococcus spp. osteoarticular infections and can be used as an alternative to amoxicillin for periprosthetic infections, including when implants are retained. The hypothesis of this study is that clindamycin is no less effective than other drugs commonly used to treat periprosthetic Streptococcus spp. infections. The primary objective of this study is to evaluate the success rate of Streptococcus spp. periprosthetic joint infections treated with clindamycin compared to other antibiotic treatments.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult patient (aged 18 years or older) at the time of surgery for infection * Probable or proven periprosthetic infection with Streptococcus spp. according to EBJIS diagnostic criteria * Patient operated on in one of the associated centers between 2013 and 2024

Exclusion criteria

* Patient who underwent joint resection or amputation * Patient who was treated with suppressive antibiotic therapy (defined as antibiotic treatment lasting more than 6 months) which was decided upon prior to surgery

Design outcomes

Primary

Measure	Time frame	Description
Therapeutic success of the medical-surgical strategy	One year after the end of antibiotic treatment	Therapeutic success of the medical-surgical strategy defined as: patient showing no clinical signs of infection, no need for repeat surgery one year after the end of antibiotic treatment, and no repeat antibiotic treatment.

Countries

France

Contacts

Primary ContactStéphane KLEIN, MD

stephane.klein@chru-strasbourg.fr33 3 68 76 52 32

Outcome results